CABOZANTINIB for Hepatocellular carcinoma: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 437 adverse event reports in the FDA FAERS database where CABOZANTINIB was used for Hepatocellular carcinoma.
Most Reported Side Effects for CABOZANTINIB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Diarrhoea | 404 | 10.6% | 71 | 263 |
| Fatigue | 263 | 6.9% | 70 | 175 |
| Malignant neoplasm progression | 238 | 6.2% | 143 | 132 |
| Nausea | 215 | 5.6% | 56 | 157 |
| Decreased appetite | 191 | 5.0% | 44 | 133 |
| Off label use | 190 | 5.0% | 71 | 76 |
| Hypertension | 165 | 4.3% | 14 | 105 |
| Pyrexia | 162 | 4.2% | 24 | 154 |
| Vomiting | 157 | 4.1% | 46 | 127 |
| Asthenia | 153 | 4.0% | 36 | 105 |
| Death | 153 | 4.0% | 153 | 47 |
| Palmar-plantar erythrodysaesthesia syndrome | 144 | 3.8% | 24 | 85 |
| Dyspnoea | 143 | 3.7% | 40 | 125 |
| Sepsis | 130 | 3.4% | 44 | 121 |
| Stomatitis | 126 | 3.3% | 19 | 84 |
Other Indications for CABOZANTINIB
Renal cell carcinoma (1,241)
Metastatic renal cell carcinoma (292)
Hormone-refractory prostate cancer (170)
Transitional cell carcinoma (136)
Thyroid cancer (125)
Non-small cell lung cancer (101)
Product used for unknown indication (94)
Renal cancer (77)
Medullary thyroid cancer (73)
Osteosarcoma (67)
Other Drugs Used for Hepatocellular carcinoma
ATEZOLIZUMAB (8,443)
BEVACIZUMAB (7,773)
LENVATINIB (5,384)
SORAFENIB (4,986)
CABOZANTINIB S-MALATE (2,670)
DURVALUMAB (1,255)
NIVOLUMAB (1,142)
REGORAFENIB (1,050)
TREMELIMUMAB\TREMELIMUMAB-ACTL (589)
PEMBROLIZUMAB (518)